Showing results (1-10 of 169) with videos related to
Sort By:
Pageof 17
Antiviral Therapy|November 13, 2004
HPV proteins as targets for therapeutic interventionHelena Sterlinko Grm, Lawrence BanksThe Journal of General Virology|September 28, 2004
Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independentHelena Sterlinko Grm, Lawrence BanksThe Indian Journal of Medical Research|November 11, 2009
Human papillomavirus infection, cancer & therapyHelena Sterlinko Grm, Martina Bergant, Lawrence BanksOncogene|April 28, 2005
Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoproteinHelena Sterlinko Grm, Paola Massimi, Noor Gammoh, et al.Journal of Virology|January 28, 2006
Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activatorNoor Gammoh, Helena Sterlinko Grm, Paola Massimi, et al.Journal of Virology|August 27, 2010
Modification of human papillomavirus minor capsid protein L2 by sumoylationMartina Bergant Marusic, Nina Mencin, Mia Licen, et al.Journal of Molecular Biology|December 31, 2003
Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptidesHelena Sterlinko Grm, Malte Weber, Rob Elston, et al.The FEBS Journal|March 4, 2021
Words of Advice: How to be a good Principal InvestigatorLawrence BanksJournal of Virology|December 3, 2010
A systematic analysis of human papillomavirus (HPV) E6 PDZ substrates identifies MAGI-1 as a major target of HPV type 16 (HPV-16) and HPV-18 whose loss accompanies disruption of tight junctionsChristian Kranjec, Lawrence BanksPageof 17